The theme: The GLP-1 complex — the large-cap manufacturers shipping today, the telehealth channel selling into patients, and the clinical-stage challengers behind them. Spans big pharma, biotech and healthcare services, so the scores span very different risk profiles.
4 of these also earn a place on the Pharmaceutical list, worth knowing before treating the two as separate bets.
The Weight-Loss Drugs group at a glance
Where these companies are filed
The 7 members report under 3 different industries, which is exactly why no standard sector view groups them:
Drug Manufacturers - General4
Biotechnology2
Drug Manufacturers - Specialty & Generic1
What kind of businesses these are
Average pillar scores across the 7 scored members, against every stock the model scores:
Pillar
Weight-Loss Drugs
Market
Read
Quality
59.0
57.7
in line
Growth
67.8
58.0
9.8 above
Value
34.9
38.4
3.5 below
Pillars run 0–100, and Value is judged against sector peers. A low Value reading means this group is expensive relative to what it earns, not that the businesses are weak.
Most of this list sits near its own top end: the median name scores 53.2 against LLY at 77.3, with VKTX at 11.2 the one straggler below. A theme is a thesis, not a quality filter — membership says a company is exposed to Weight-Loss Drugs, and the score says what the model makes of the business.
Where analysts are moving on Weight-Loss Drugs
Across the 6 Weight-Loss Drugs names with a reading, the median forward earnings estimate is rising — +3.2% over 90 days, ahead of the market (+0.5%). The split is one-sided: 4 of the 6 moving up against 2 down.
Estimates implied by price ÷ forward P/E, captured together each trading day since June 2026, and outside the Bull Rankings score. 6 of 7 members carry a reading; the rest have no forward P/E to imply one from, which is normal for loss-makers. How this is measured, across the market →
Common questions
What counts as a Weight-Loss Drugs stock?
The GLP-1 complex — the large-cap manufacturers shipping today, the telehealth channel selling into patients, and the clinical-stage challengers behind them. Spans big pharma, biotech and healthcare services, so the scores span very different risk profiles. The companies are hand-picked by Bartholomew Chupka Jr., the site's founder, from the stocks in our US coverage.
How are the best Weight-Loss Drugs stocks ranked?
Each name is scored on the Bull Rankings quality-growth model — one 0–100 score blending business quality, growth, and valuation — the same score used everywhere on the site.
Are analysts raising or cutting Weight-Loss Drugs earnings estimates?
Across the 6 Weight-Loss Drugs names with a reading, the median forward earnings estimate is rising — +3.2% over 90 days, ahead of the market (+0.5%). The split is one-sided: 4 of the 6 moving up against 2 down. Estimates are implied by price divided by forward P/E, captured together each trading day so only a changed forecast moves the figure, and they sit outside the Bull Rankings score.
How often is the ranking updated?
The universe is re-scored every trading day after the US market close, so the ranking reflects the latest fundamentals and prices.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.